BACKGROUND: Several studies demonstrated that intraoperative near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) identifies (sub)capsular colorectal liver metastases (CRLM) missed by other techniques. It is unclear if this results in any survival benefit. This study evaluates long-term follow-up after NIRF-guided resection of CRLM using ICG. METHODS: First, patients undergoing resection of CRLM with or without NIRF imaging were analyzed retrospectively. Perioperative details, liver-specific recurrence-free interval and overall survival were compared. Second, the prognosis of patients in whom additional metastases were identified solely by NIRF was studied. RESULTS: Eighty-six patients underwent resection with NIRF imaging and 87 without. In significantly more patients of the NIRF imaging cohort additional metastases were identified during surgery (25% vs. 13%, p = 0.04). Tumors identified solely by NIRF imaging were significantly smaller compared to additional metastases identified also by inspection, palpation or intraoperative ultrasound (3.2 ± 1.8 mm vs. 7.4 ± 2.6 mm, p < 0.001). Liver-specific recurrence-free survival at 4 years was 47% with NIRF imaging and 39% without (hazard ratio at multivariate analysis 0.73, 95% CI 0.42-1.28, p = 0.28). Overall survival at 4 years was 62% and 59%, respectively (p = 0.79). No liver recurrences occurred within 3 years follow-up in 52% of patients in whom additional metastases were resected based on only NIRF imaging. CONCLUSIONS: This study suggests that NIRF imaging identifies significantly more and smaller tumors during resection of CRLM, preventing recurrences in a subset of patients. Given its safety profile and low expense, routine use can be considered until tumor targeting fluorescent tracers are clinically available.
BACKGROUND: Several studies demonstrated that intraoperative near-infrared fluorescence (NIRF) imaging using indocyanine green (ICG) identifies (sub)capsular colorectal liver metastases (CRLM) missed by other techniques. It is unclear if this results in any survival benefit. This study evaluates long-term follow-up after NIRF-guided resection of CRLM using ICG. METHODS: First, patients undergoing resection of CRLM with or without NIRF imaging were analyzed retrospectively. Perioperative details, liver-specific recurrence-free interval and overall survival were compared. Second, the prognosis of patients in whom additional metastases were identified solely by NIRF was studied. RESULTS: Eighty-six patients underwent resection with NIRF imaging and 87 without. In significantly more patients of the NIRF imaging cohort additional metastases were identified during surgery (25% vs. 13%, p = 0.04). Tumors identified solely by NIRF imaging were significantly smaller compared to additional metastases identified also by inspection, palpation or intraoperative ultrasound (3.2 ± 1.8 mm vs. 7.4 ± 2.6 mm, p < 0.001). Liver-specific recurrence-free survival at 4 years was 47% with NIRF imaging and 39% without (hazard ratio at multivariate analysis 0.73, 95% CI 0.42-1.28, p = 0.28). Overall survival at 4 years was 62% and 59%, respectively (p = 0.79). No liver recurrences occurred within 3 years follow-up in 52% of patients in whom additional metastases were resected based on only NIRF imaging. CONCLUSIONS: This study suggests that NIRF imaging identifies significantly more and smaller tumors during resection of CRLM, preventing recurrences in a subset of patients. Given its safety profile and low expense, routine use can be considered until tumor targeting fluorescent tracers are clinically available.
Authors: Leonora S F Boogerd; Henricus J M Handgraaf; Hwai-Ding Lam; Andries E Braat; Andrzej G Baranski; Rutger-Jan Swijnenburg; John V Frangioni; Alexander L Vahrmeijer; Jan Ringers Journal: Surgery Date: 2016-01-23 Impact factor: 3.982
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen Journal: Neurosurgery Date: 1998-03 Impact factor: 4.654
Authors: Henricus J M Handgraaf; Floris P R Verbeek; Quirijn R J G Tummers; Leonora S F Boogerd; Cornelis J H van de Velde; Alexander L Vahrmeijer; Katja N Gaarenstroom Journal: Gynecol Oncol Date: 2014-08-11 Impact factor: 5.482
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Floris P R Verbeek; Gerrit-Jan Liefers; Henk H Hartgrink; Vincent T H B M Smit; Clemens W G M Löwik; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Laetitia E Lamberts; Maximillian Koch; Johannes S de Jong; Arthur L L Adams; Jürgen Glatz; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G Elias; Sabrina Oliveira; Arjen J Witkamp; Willem P Th M Mali; Elsken Van der Wall; Paul J van Diest; Elisabeth G E de Vries; Vasilis Ntziachristos; Gooitzen M van Dam Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531
Authors: Susan L Troyan; Vida Kianzad; Summer L Gibbs-Strauss; Sylvain Gioux; Aya Matsui; Rafiou Oketokoun; Long Ngo; Ali Khamene; Fred Azar; John V Frangioni Journal: Ann Surg Oncol Date: 2009-07-07 Impact factor: 5.344
Authors: Mitchell S Fourman; Adel Mahjoub; Jon B Mandell; Shibing Yu; Jessica C Tebbets; Jared A Crasto; Peter E Alexander; Kurt R Weiss Journal: Clin Orthop Relat Res Date: 2018-03 Impact factor: 4.176
Authors: Ishaan Patel; David Bartlett; Bobby V Dasari; Nikolaos Chatzizacharias; John Isaac; Ravi Marudanayagam; Darius F Mirza; J Keith Roberts; Robert P Sutcliffe Journal: J Gastrointest Cancer Date: 2022-05-26
Authors: Anne-Sophie Mehdorn; Florian Richter; Katharina Hess; Jan Henrik Beckmann; Jan-Hendrik Egberts; Michael Linecker; Thomas Becker; Felix Braun Journal: J Clin Med Date: 2022-06-19 Impact factor: 4.964
Authors: Vincent Q Sier; Joost R van der Vorst; Paul H A Quax; Margreet R de Vries; Elham Zonoobi; Alexander L Vahrmeijer; Ilona A Dekkers; Lioe-Fee de Geus-Oei; Anke M Smits; Weibo Cai; Cornelis F M Sier; Marie José T H Goumans; Lukas J A C Hawinkels Journal: Int J Mol Sci Date: 2021-04-30 Impact factor: 5.923
Authors: Andreas Hackethal; Markus Hirschburger; Sven Oliver Eicker; Thomas Mücke; Christoph Lindner; Olaf Buchweitz Journal: Geburtshilfe Frauenheilkd Date: 2018-01-22 Impact factor: 2.915